title: alpha-Internexin expression identifies 1p19q codeleted gliomas.
abstract: BACKGROUND
  alpha-Internexin (INA) is a proneural gene encoding a neurofilament interacting protein that is upregulated in some gliomas, particularly oligodendrogliomas.
  
  
  METHODS
  INA expression was evaluated by immunohistochemistry in a series of 122 gliomas, and correlated to the 1p19q codeletion, a favorable prognostic marker of oligodendroglial tumors.
  
  
  RESULTS
  INA expression was strong (>10% positive cells) in 22 cases (22 oligodendroglial tumors and 0 astrocytic tumors), weak (<10% cells) in 14 cases (12 oligodendroglial tumors, 2 glioblastoma with an oligodendroglial component, and 0 astrocytic tumors), and negative in 86 cases (49 oligodendroglial tumors, 9 glioblastoma with an oligodendroglial component, and 28 astrocytic tumors). Among the 27 tumors exhibiting the 1p19q codeletion (all with an oligodendroglial phenotype), INA was detected in 96% (26/27, 18 strong, 8 weak) as compared to 11% (10/95, 4 strong, 6 weak) in the tumors without 1p19q codeletion (with an oligodendroglial or an astrocytic phenotype) (p < 0.001). In oligodendroglial tumors, INA expression specificity for 1p19q codeletion was 86%, sensitivity 96%, positive predictive value 76%, and negative predictive value was 98%. The prognostic impact of INA expression could be evaluated in grade III oligodendroglial tumors. Similar to 1p19q deletion, positive INA expression was correlated with better progression-free survival (52.6 vs 8.7 months [p = 0.001]) and overall survival (121.1 vs 31.4 months [p = 0.0001]).
  
  
  CONCLUSIONS
  alpha-Internexin (INA) expression appears to be a simple, reliable prognostic marker and a surrogate marker of 1p19q codeletion.
authors.affiliation: Unité INSERM U711, Service de Neurologie Mazarin, CHU Pitié-Salpêtrière, Université Paris VI, France.
authors.forename: F
authors.initials: F
authors.lastname: Ducray
authors.forename: E
authors.initials: E
authors.lastname: Crinière
authors.forename: A
authors.initials: A
authors.lastname: Idbaih
authors.forename: K
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Y
authors.initials: Y
authors.lastname: Marie
authors.forename: S
authors.initials: S
authors.lastname: Paris
authors.forename: S
authors.initials: S
authors.lastname: Navarro
authors.forename: F
authors.initials: F
authors.lastname: Laigle-Donadey
authors.forename: C
authors.initials: C
authors.lastname: Dehais
authors.forename: J
authors.initials: J
authors.lastname: Thillet
authors.forename: K
authors.initials: K
authors.lastname: Hoang-Xuan
authors.forename: J-Y
authors.initials: JY
authors.lastname: Delattre
authors.forename: M
authors.initials: M
authors.lastname: Sanson
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics*; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics*; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics*; D004252:DNA Mutational Analysis; D018450:Disease Progression; D017353:Gene Deletion; D005796:Genes; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D005910:Glioma / Q000175:diagnosis / Q000235:genetics*; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics*; D009154:Mutation / Q000235:genetics; D009837:Oligodendroglioma / Q000175:diagnosis / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D007381:Intermediate Filament Proteins; C046643:alpha-internexin